English

NAVIDEA BIOPHARMACEUTICALS, INC.

EDGAR

NAVB Quarterly report (10-Q) · filed 2023-11-14

135 filing records in this dataset, filed from 1996-05-15 to 2023-11-14. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2023 Q3 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-10.2 million USD

2023 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -7280619 USD Source
Operating Cash Flow: 2968333 USD Source

Free cash flow

-10.2 million USD

2023 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -7280619 USD Source
Operating Cash Flow: 2968333 USD Source
Capital Expenditure: 15068 USD Source
Capital Expenditure: 15068 USD Source

Cash and cash equivalents: 3.86 million USD 2023-09-30 Source
Exact value

3864822 USD
Long-term debt including current maturities: Not available
Shares outstanding: 100 million shares 2023-09-30 Source
Exact value

100084385 shares

Reported share-count change

211.30% · 67.9 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

32150918 shares · 2022-09-30· Source
100084385 shares · 2023-09-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-11-14.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2022-12-31
Operating income: 8 of 11 periods available· newest 2022-12-31
Net income: 7 of 11 periods available· newest 2022-12-31
Operating cash flow: 8 of 11 periods available· newest 2022-12-31
Capital expenditure: 8 of 11 periods available· newest 2022-12-31
Total assets: 8 of 11 periods available· newest 2022-12-31
Total liabilities: 8 of 11 periods available· newest 2022-12-31
Current assets: 8 of 11 periods available· newest 2022-12-31
Current liabilities: 8 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2022-12-31
long term debt: No compatible figures in this window
Shares outstanding: 8 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-87.6%

Prior period

USD 531,513

2021-01-01 – 2021-12-31
Current period

USD 65,652

2022-01-01 – 2022-12-31

Exact inputs and evidence

65652 − 531513 = -465861 USD

531513 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
65652 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · NAVIDEA BIOPHARMACEUTICALS, INC. · 2022-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Year-over-year change in Revenue: -465861 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 65652 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#2307414 Filing: 000143774923008054 Input fundies:Revenue: 531513 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#2360529 Filing: 000143774923008054
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 3.45 million

Prior period

−USD 11.73 million

2021-01-01 – 2021-12-31
Current period

−USD 15.18 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-15177153 − -11730927 = -3446226 USD

-11730927 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-15177153 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · NAVIDEA BIOPHARMACEUTICALS, INC. · 2022-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Year-over-year change in Net income: -3446226 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -15177153 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#1351161 Filing: 000143774923008054 Input fundies:NetIncome: -11730927 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#1351787 Filing: 000143774923008054
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 1.23 million

Prior period

−USD 10.22 million

2021-01-01 – 2021-12-31
Current period

−USD 8.99 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-8986570 − -10218155 = 1231585 USD

-10218155 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-8986570 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2022-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Year-over-year change in Operating cash flow: 1231585 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -8986570 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#1736838 Filing: 000143774923008054 Input fundies:OperatingCashFlow: -10218155 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#1737689 Filing: 000143774923008054
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+150.2%

Prior period

USD 25,218

2021-01-01 – 2021-12-31
Current period

USD 63,086

2022-01-01 – 2022-12-31

Exact inputs and evidence

63086 − 25218 = 37868 USD

25218 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
63086 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · NAVIDEA BIOPHARMACEUTICALS, INC. · 2022-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Year-over-year change in Capital expenditure: 37868 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 63086 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#2344625 Filing: 000143774923008054 Input fundies:CapitalExpenditure: 25218 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#2395083 Filing: 000143774923008054
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 65,652 100% of revenue
Cost of revenue USD 1,941 3% of revenue
Operating expenses USD 13.93 million 21,220% of revenue
Other operating costs Derived USD 183,006 279% of revenue
Operating income −USD 14.05 million −21,402% of revenue
Tax, interest and other Derived USD 1.13 million 1,715% of revenue
Net income −USD 15.18 million −23,118% of revenue

Cash

Operating cash flow −USD 8.99 million −13,688% of revenue
Capital expenditure USD 63,086 96% of revenue
Free cash flow Derived −USD 9.05 million −13,784% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2012 Not shown: operating income or net income is not reported.
2013 Operating loss: operating costs were 3,500% of revenue.
2014 Operating loss: operating costs were 540% of revenue.
2015 Operating loss: operating costs were 240% of revenue.
2016 Operating loss: operating costs were 110% of revenue.
2020 Not shown: operating income or net income is not reported.
2021 Operating loss: operating costs were 2,369% of revenue.
2022 Operating loss: operating costs were 21,502% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2012 2012-01-01 – 2012-12-31	0	27989303 Derived	-27989303	1167901 Derived	-29157204	-24586667 Derived	Source 2012-01-01 – 2012-12-31: 0 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -27989303 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -29157204 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -23923319 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 663348 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	1130630	39568944 Derived	-38438314	4261144 Derived	-42699458	-36851741 Derived	Source 2013-01-01 – 2013-12-31: 1130630 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -38438314 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -42699458 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -35612075 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 1239666 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	6274849	33907805 Derived	-27632956	8093713 Derived	-35726669	-30241197 Derived	Source 2014-01-01 – 2014-12-31: 6274849 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -27632956 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -35726669 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -29126749 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 1114448 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	13249307	31799825 Derived	-18550518	9013017 Derived	-27563535	-19115031 Derived	Source 2015-01-01 – 2015-12-31: 13249307 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -18550518 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -27563535 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -19076030 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 39001 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	21969706	24193181 Derived	-2223475	12085556 Derived	-14309031	3554933 Derived	Source 2016-01-01 – 2016-12-31: 21969706 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -2223475 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -14309031 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 3556780 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 1847 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	915013	11626194 Derived	-10711181	Unavailable	Unavailable	-8309674 Derived	Source 2020-01-01 – 2020-12-31: 915013 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -10711181 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -8173793 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 135881 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	531513	12591925 Derived	-12060412	-329485 Derived	-11730927	-10243373 Derived	Source 2021-01-01 – 2021-12-31: 531513 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -12060412 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -11730927 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -10218155 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 25218 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	65652	14116547 Derived	-14050895	1126258 Derived	-15177153	-9049656 Derived	Source 2022-01-01 – 2022-12-31: 65652 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -14050895 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -15177153 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -8986570 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 63086 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 65.7K 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Revenue	0	Revenue: 0 Open source
20132013-12-31	Revenue	1130630	Revenue: 1130630 Open source
20142014-12-31	Revenue	6274849	Revenue: 6274849 Open source
20152015-12-31	Revenue	13249307	Revenue: 13249307 Open source
20162016-12-31	Revenue	21969706	Revenue: 21969706 Open source
20202020-12-31	Revenue	915013	Revenue: 915013 Open source
20212021-12-31	Revenue	531513	Revenue: 531513 Open source
20222022-12-31	Revenue	65652	Revenue: 65652 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-87.6% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20132013-12-31	Year over year	No prior comparable period	Revenue: 1130630 Open source Revenue: 0 Open source
20142014-12-31	Year over year	455%	Revenue: 6274849 Open source Revenue: 1130630 Open source
20152015-12-31	Year over year	111.1%	Revenue: 13249307 Open source Revenue: 6274849 Open source
20162016-12-31	Year over year	65.8%	Revenue: 21969706 Open source Revenue: 13249307 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 915013 Open source
20212021-12-31	Year over year	-41.9%	Revenue: 531513 Open source Revenue: 915013 Open source
20222022-12-31	Year over year	-87.6%	Revenue: 65652 Open source Revenue: 531513 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -21,402.1% 2022

Net margin -23,117.6% 2022

Free cash flow margin -13,784.3% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Operating margin	Not reported	Operating Income: -27989303 Open source Revenue: 0 Open source
20132013-12-31	Operating margin	-3,399.7%	Operating Income: -38438314 Open source Revenue: 1130630 Open source
20142014-12-31	Operating margin	-440.4%	Operating Income: -27632956 Open source Revenue: 6274849 Open source
20152015-12-31	Operating margin	-140%	Operating Income: -18550518 Open source Revenue: 13249307 Open source
20162016-12-31	Operating margin	-10.1%	Operating Income: -2223475 Open source Revenue: 21969706 Open source
20202020-12-31	Operating margin	-1,170.6%	Operating Income: -10711181 Open source Revenue: 915013 Open source
20212021-12-31	Operating margin	-2,269.1%	Operating Income: -12060412 Open source Revenue: 531513 Open source
20222022-12-31	Operating margin	-21,402.1%	Operating Income: -14050895 Open source Revenue: 65652 Open source
20122012-12-31	Net margin	Not reported	Net Income: -29157204 Open source Revenue: 0 Open source
20132013-12-31	Net margin	-3,776.6%	Net Income: -42699458 Open source Revenue: 1130630 Open source
20142014-12-31	Net margin	-569.4%	Net Income: -35726669 Open source Revenue: 6274849 Open source
20152015-12-31	Net margin	-208%	Net Income: -27563535 Open source Revenue: 13249307 Open source
20162016-12-31	Net margin	-65.1%	Net Income: -14309031 Open source Revenue: 21969706 Open source
2020-12-31	Net margin	Not reported	Revenue: 915013 Open source
20212021-12-31	Net margin	-2,207.1%	Net Income: -11730927 Open source Revenue: 531513 Open source
20222022-12-31	Net margin	-23,117.6%	Net Income: -15177153 Open source Revenue: 65652 Open source
20122012-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -23923319 Open source Capital Expenditure: 663348 Open source
20132013-12-31	Free cash flow margin	-3,259.4%	Revenue: 1130630 Open source Operating Cash Flow: -35612075 Open source Capital Expenditure: 1239666 Open source
20142014-12-31	Free cash flow margin	-481.9%	Revenue: 6274849 Open source Operating Cash Flow: -29126749 Open source Capital Expenditure: 1114448 Open source
20152015-12-31	Free cash flow margin	-144.3%	Revenue: 13249307 Open source Operating Cash Flow: -19076030 Open source Capital Expenditure: 39001 Open source
20162016-12-31	Free cash flow margin	16.2%	Revenue: 21969706 Open source Operating Cash Flow: 3556780 Open source Capital Expenditure: 1847 Open source
20202020-12-31	Free cash flow margin	-908.1%	Revenue: 915013 Open source Operating Cash Flow: -8173793 Open source Capital Expenditure: 135881 Open source
20212021-12-31	Free cash flow margin	-1,927.2%	Revenue: 531513 Open source Operating Cash Flow: -10218155 Open source Capital Expenditure: 25218 Open source
20222022-12-31	Free cash flow margin	-13,784.3%	Revenue: 65652 Open source Operating Cash Flow: -8986570 Open source Capital Expenditure: 63086 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -9M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Operating cash flow	-23923319	Operating Cash Flow: -23923319 Open source
20132013-12-31	Operating cash flow	-35612075	Operating Cash Flow: -35612075 Open source
20142014-12-31	Operating cash flow	-29126749	Operating Cash Flow: -29126749 Open source
20152015-12-31	Operating cash flow	-19076030	Operating Cash Flow: -19076030 Open source
20162016-12-31	Operating cash flow	3556780	Operating Cash Flow: 3556780 Open source
20202020-12-31	Operating cash flow	-8173793	Operating Cash Flow: -8173793 Open source
20212021-12-31	Operating cash flow	-10218155	Operating Cash Flow: -10218155 Open source
20222022-12-31	Operating cash flow	-8986570	Operating Cash Flow: -8986570 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -9M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Free cash flow	-24586667	Operating Cash Flow: -23923319 Open source Capital Expenditure: 663348 Open source
20132013-12-31	Free cash flow	-36851741	Operating Cash Flow: -35612075 Open source Capital Expenditure: 1239666 Open source
20142014-12-31	Free cash flow	-30241197	Operating Cash Flow: -29126749 Open source Capital Expenditure: 1114448 Open source
20152015-12-31	Free cash flow	-19115031	Operating Cash Flow: -19076030 Open source Capital Expenditure: 39001 Open source
20162016-12-31	Free cash flow	3554933	Operating Cash Flow: 3556780 Open source Capital Expenditure: 1847 Open source
20202020-12-31	Free cash flow	-8309674	Operating Cash Flow: -8173793 Open source Capital Expenditure: 135881 Open source
20212021-12-31	Free cash flow	-10243373	Operating Cash Flow: -10218155 Open source Capital Expenditure: 25218 Open source
20222022-12-31	Free cash flow	-9049656	Operating Cash Flow: -8986570 Open source Capital Expenditure: 63086 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

286.3% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Liabilities / assets	111.7%	Total Liabilities: 13377773 Open source Total Assets: 11972397 Open source
20132013-12-31	Liabilities / assets	109.9%	Total Liabilities: 44326104 Open source Total Assets: 40316517 Open source
20142014-12-31	Liabilities / assets	351.9%	Total Liabilities: 41633774 Open source Total Assets: 11830308 Open source
20152015-12-31	Liabilities / assets	459.8%	Total Liabilities: 68800213 Open source Total Assets: 14964513 Open source
20162016-12-31	Liabilities / assets	643%	Total Liabilities: 80127889 Open source Total Assets: 12461676 Open source
20202020-12-31	Liabilities / assets	73.6%	Total Liabilities: 5711111 Open source Total Assets: 7758018 Open source
20212021-12-31	Liabilities / assets	90.6%	Total Liabilities: 6020090 Open source Total Assets: 6644833 Open source
20222022-12-31	Liabilities / assets	286.3%	Total Liabilities: 12514916 Open source Total Assets: 4371606 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.32× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Current assets / current liabilities	1.72×	Current Assets: 10617383 Open source Current Liabilities: 6190539 Open source
20132013-12-31	Current assets / current liabilities	3.31×	Current Assets: 37331182 Open source Current Liabilities: 11290962 Open source
20142014-12-31	Current assets / current liabilities	0.95×	Current Assets: 8599145 Open source Current Liabilities: 9060297 Open source
20152015-12-31	Current assets / current liabilities	2.03×	Current Assets: 12577174 Open source Current Liabilities: 6183850 Open source
20162016-12-31	Current assets / current liabilities	0.15×	Current Assets: 10826269 Open source Current Liabilities: 69861788 Open source
20202020-12-31	Current assets / current liabilities	1.38×	Current Assets: 6528328 Open source Current Liabilities: 4715105 Open source
20212021-12-31	Current assets / current liabilities	1.02×	Current Assets: 5383285 Open source Current Liabilities: 5299802 Open source
20222022-12-31	Current assets / current liabilities	0.32×	Current Assets: 3203944 Open source Current Liabilities: 9941889 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2012-01-01 – 2012-12-31	−USD 29.16 million Exact value Exact value: -29157204 USD 2012-01-01 – 2012-12-31: -29157204 USD Inspect Net Income Open source Share or cite Citation for Net Income · NAVIDEA BIOPHARMACEUTICALS, INC. · 2012-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Net Income: -29157204 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29157204 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000081050915000003/navb-20141231.xml#332275 Filing: 000081050915000003 The citation records this snapshot. The page link may show a newer release later.	−USD 23.92 million Exact value Exact value: -23923319 USD 2012-01-01 – 2012-12-31: -23923319 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2012-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Operating Cash Flow: -23923319 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23923319 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000081050915000003/navb-20141231.xml#331642 Filing: 000081050915000003 The citation records this snapshot. The page link may show a newer release later.	USD 663,348 Exact value Exact value: 663348 USD 2012-01-01 – 2012-12-31: 663348 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NAVIDEA BIOPHARMACEUTICALS, INC. · 2012-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Capital Expenditure: 663348 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 663348 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000081050915000003/navb-20141231.xml#359387 Filing: 000081050915000003 The citation records this snapshot. The page link may show a newer release later.	−USD 24.59 million Calculation and evidence -23923319 − 663348 USD Exact free cash flow: -24586667 USD 2012-01-01 – 2012-12-31: -23923319 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 663348 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2012-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Free cash flow: -24586667 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23923319 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000081050915000003/navb-20141231.xml#331642 Filing: 000081050915000003 Input fundies:CapitalExpenditure: 663348 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000081050915000003/navb-20141231.xml#359387 Filing: 000081050915000003 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 42.7 million Exact value Exact value: -42699458 USD 2013-01-01 – 2013-12-31: -42699458 USD Inspect Net Income Open source Share or cite Citation for Net Income · NAVIDEA BIOPHARMACEUTICALS, INC. · 2013-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Net Income: -42699458 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42699458 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000081050915000003/navb-20141231.xml#333265 Filing: 000081050915000003 The citation records this snapshot. The page link may show a newer release later.	−USD 35.61 million Exact value Exact value: -35612075 USD 2013-01-01 – 2013-12-31: -35612075 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2013-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Operating Cash Flow: -35612075 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35612075 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000156459016015173/navb-20151231.xml#303495 Filing: 000156459016015173 The citation records this snapshot. The page link may show a newer release later.	USD 1.24 million Exact value Exact value: 1239666 USD 2013-01-01 – 2013-12-31: 1239666 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NAVIDEA BIOPHARMACEUTICALS, INC. · 2013-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Capital Expenditure: 1239666 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1239666 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000156459016015173/navb-20151231.xml#304162 Filing: 000156459016015173 The citation records this snapshot. The page link may show a newer release later.	−USD 36.85 million Calculation and evidence -35612075 − 1239666 USD Exact free cash flow: -36851741 USD 2013-01-01 – 2013-12-31: -35612075 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 1239666 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2013-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Free cash flow: -36851741 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35612075 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000156459016015173/navb-20151231.xml#303495 Filing: 000156459016015173 Input fundies:CapitalExpenditure: 1239666 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000156459016015173/navb-20151231.xml#304162 Filing: 000156459016015173 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 35.73 million Exact value Exact value: -35726669 USD 2014-01-01 – 2014-12-31: -35726669 USD Inspect Net Income Open source Share or cite Citation for Net Income · NAVIDEA BIOPHARMACEUTICALS, INC. · 2014-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Net Income: -35726669 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -35726669 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#199163 Filing: 000165495417002915 The citation records this snapshot. The page link may show a newer release later.	−USD 29.13 million Exact value Exact value: -29126749 USD 2014-01-01 – 2014-12-31: -29126749 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2014-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Operating Cash Flow: -29126749 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29126749 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#209414 Filing: 000165495417002915 The citation records this snapshot. The page link may show a newer release later.	USD 1.11 million Exact value Exact value: 1114448 USD 2014-01-01 – 2014-12-31: 1114448 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NAVIDEA BIOPHARMACEUTICALS, INC. · 2014-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Capital Expenditure: 1114448 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1114448 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#219958 Filing: 000165495417002915 The citation records this snapshot. The page link may show a newer release later.	−USD 30.24 million Calculation and evidence -29126749 − 1114448 USD Exact free cash flow: -30241197 USD 2014-01-01 – 2014-12-31: -29126749 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 1114448 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2014-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Free cash flow: -30241197 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29126749 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#209414 Filing: 000165495417002915 Input fundies:CapitalExpenditure: 1114448 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#219958 Filing: 000165495417002915 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 27.56 million Exact value Exact value: -27563535 USD 2015-01-01 – 2015-12-31: -27563535 USD Inspect Net Income Open source Share or cite Citation for Net Income · NAVIDEA BIOPHARMACEUTICALS, INC. · 2015-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Net Income: -27563535 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27563535 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#199022 Filing: 000165495417002915 The citation records this snapshot. The page link may show a newer release later.	−USD 19.08 million Exact value Exact value: -19076030 USD 2015-01-01 – 2015-12-31: -19076030 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2015-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Operating Cash Flow: -19076030 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19076030 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#209175 Filing: 000165495417002915 The citation records this snapshot. The page link may show a newer release later.	USD 39,001 Exact value Exact value: 39001 USD 2015-01-01 – 2015-12-31: 39001 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NAVIDEA BIOPHARMACEUTICALS, INC. · 2015-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Capital Expenditure: 39001 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 39001 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#219763 Filing: 000165495417002915 The citation records this snapshot. The page link may show a newer release later.	−USD 19.12 million Calculation and evidence -19076030 − 39001 USD Exact free cash flow: -19115031 USD 2015-01-01 – 2015-12-31: -19076030 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 39001 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2015-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Free cash flow: -19115031 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19076030 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#209175 Filing: 000165495417002915 Input fundies:CapitalExpenditure: 39001 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#219763 Filing: 000165495417002915 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 14.31 million Exact value Exact value: -14309031 USD 2016-01-01 – 2016-12-31: -14309031 USD Inspect Net Income Open source Share or cite Citation for Net Income · NAVIDEA BIOPHARMACEUTICALS, INC. · 2016-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Net Income: -14309031 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14309031 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#198881 Filing: 000165495417002915 The citation records this snapshot. The page link may show a newer release later.	USD 3.56 million Exact value Exact value: 3556780 USD 2016-01-01 – 2016-12-31: 3556780 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2016-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Operating Cash Flow: 3556780 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 3556780 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#208938 Filing: 000165495417002915 The citation records this snapshot. The page link may show a newer release later.	USD 1,847 Exact value Exact value: 1847 USD 2016-01-01 – 2016-12-31: 1847 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NAVIDEA BIOPHARMACEUTICALS, INC. · 2016-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Capital Expenditure: 1847 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1847 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#219569 Filing: 000165495417002915 The citation records this snapshot. The page link may show a newer release later.	USD 3.55 million Calculation and evidence 3556780 − 1847 USD Exact free cash flow: 3554933 USD 2016-01-01 – 2016-12-31: 3556780 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 1847 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2016-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Free cash flow: 3554933 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 3556780 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#208938 Filing: 000165495417002915 Input fundies:CapitalExpenditure: 1847 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000165495417002915/navb-20161231.xml#219569 Filing: 000165495417002915 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	Unavailable Not reported for this period.	−USD 8.17 million Exact value Exact value: -8173793 USD 2020-01-01 – 2020-12-31: -8173793 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2020-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Operating Cash Flow: -8173793 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8173793 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774922007390/navb20211231_10k.htm#1817982 Filing: 000143774922007390 The citation records this snapshot. The page link may show a newer release later.	USD 135,881 Exact value Exact value: 135881 USD 2020-01-01 – 2020-12-31: 135881 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NAVIDEA BIOPHARMACEUTICALS, INC. · 2020-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Capital Expenditure: 135881 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 135881 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774922007390/navb20211231_10k.htm#2455296 Filing: 000143774922007390 The citation records this snapshot. The page link may show a newer release later.	−USD 8.31 million Calculation and evidence -8173793 − 135881 USD Exact free cash flow: -8309674 USD 2020-01-01 – 2020-12-31: -8173793 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 135881 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2020-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Free cash flow: -8309674 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8173793 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774922007390/navb20211231_10k.htm#1817982 Filing: 000143774922007390 Input fundies:CapitalExpenditure: 135881 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774922007390/navb20211231_10k.htm#2455296 Filing: 000143774922007390 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 11.73 million Exact value Exact value: -11730927 USD 2021-01-01 – 2021-12-31: -11730927 USD Inspect Net Income Open source Share or cite Citation for Net Income · NAVIDEA BIOPHARMACEUTICALS, INC. · 2021-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Net Income: -11730927 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11730927 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#1351787 Filing: 000143774923008054 The citation records this snapshot. The page link may show a newer release later.	−USD 10.22 million Exact value Exact value: -10218155 USD 2021-01-01 – 2021-12-31: -10218155 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2021-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Operating Cash Flow: -10218155 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10218155 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#1737689 Filing: 000143774923008054 The citation records this snapshot. The page link may show a newer release later.	USD 25,218 Exact value Exact value: 25218 USD 2021-01-01 – 2021-12-31: 25218 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NAVIDEA BIOPHARMACEUTICALS, INC. · 2021-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Capital Expenditure: 25218 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 25218 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#2395083 Filing: 000143774923008054 The citation records this snapshot. The page link may show a newer release later.	−USD 10.24 million Calculation and evidence -10218155 − 25218 USD Exact free cash flow: -10243373 USD 2021-01-01 – 2021-12-31: -10218155 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 25218 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2021-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Free cash flow: -10243373 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10218155 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#1737689 Filing: 000143774923008054 Input fundies:CapitalExpenditure: 25218 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#2395083 Filing: 000143774923008054 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 15.18 million Exact value Exact value: -15177153 USD 2022-01-01 – 2022-12-31: -15177153 USD Inspect Net Income Open source Share or cite Citation for Net Income · NAVIDEA BIOPHARMACEUTICALS, INC. · 2022-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Net Income: -15177153 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -15177153 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#1351161 Filing: 000143774923008054 The citation records this snapshot. The page link may show a newer release later.	−USD 8.99 million Exact value Exact value: -8986570 USD 2022-01-01 – 2022-12-31: -8986570 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2022-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Operating Cash Flow: -8986570 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8986570 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#1736838 Filing: 000143774923008054 The citation records this snapshot. The page link may show a newer release later.	USD 63,086 Exact value Exact value: 63086 USD 2022-01-01 – 2022-12-31: 63086 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NAVIDEA BIOPHARMACEUTICALS, INC. · 2022-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Capital Expenditure: 63086 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 63086 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#2344625 Filing: 000143774923008054 The citation records this snapshot. The page link may show a newer release later.	−USD 9.05 million Calculation and evidence -8986570 − 63086 USD Exact free cash flow: -9049656 USD 2022-01-01 – 2022-12-31: -8986570 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 63086 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NAVIDEA BIOPHARMACEUTICALS, INC. · 2022-12-31 NAVIDEA BIOPHARMACEUTICALS, INC. (edgar:810509) Free cash flow: -9049656 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/810509?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8986570 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#1736838 Filing: 000143774923008054 Input fundies:CapitalExpenditure: 63086 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm#2344625 Filing: 000143774923008054 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

135 filings · 4,981 latest values · 5,010 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000810509, 810509, NAVB, NEOP, edgar:810509, navb

Also known as NAVIDEA BIOPHARMACEUTICALS, INC., NEOPROBE CORP

NAVIDEA BIOPHARMACEUTICALS, INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation